638220-35-6

Basic information

• Product Name: Methyl 1-(4-bromophenyl)cyclopropanecarboxylate
• Synonyms: Methyl 1-(4-bromophenyl)cyclopropanecarboxylate;1-(4-BroMo-phenyl)-cyclopropanecarboxylic acid Methyl ester;methyl 1-(4-bromophenyl)cyclopropane-1-carboxylate
• CAS NO: 638220-35-6
• Molecular Formula: C₁₁H₁₁BrO₂
• Molecular Weight: 255.10784
• Mol File: 638220-35-6.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 290.4±33.0 °C(Predicted)
• Appearance: /
• Density: 1.503±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 1-(4-bromophenyl)cyclopropanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-(4-bromophenyl)cyclopropanecarboxylate(638220-35-6)
• EPA Substance Registry System: Methyl 1-(4-bromophenyl)cyclopropanecarboxylate(638220-35-6)

Safety Data

• Hazardous Substances Data: 638220-35-6(Hazardous Substances Data)

Usage

General Description

Methyl 1-(4-bromophenyl)cyclopropanecarboxylate is a chemical compound with the molecular formula C11H11BrO2. It is an ester, which means it is derived from an acid in which at least one hydrogen atom is replaced by an alkyl group. Methyl 1-(4-bromophenyl)cyclopropanecarboxylate has a cyclopropane ring, which is a highly strained and reactive three-membered ring. The presence of the bromophenyl group indicates that it contains a benzene ring with a bromine atom attached to it. Methyl 1-(4-bromophenyl)cyclopropanecarboxylate may have applications in organic synthesis, pharmaceuticals, or agrochemicals due to its unique structure and functional groups. It is important to handle this compound with caution and follow proper safety protocols when working with it in a laboratory or industrial setting.

Upstream product

• 186581-53-3 diazomethane 
• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 75-36-5 acetyl chloride 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 124276-67-1 1-(4-bromophenyl)cyclopropanecarbonitrile 
• 16532-79-9 4-Bromophenylacetonitrile 
• 106-93-4 ethylene dibromide 
• 75-77-4 chloro-trimethyl-silane 

Downstream Products

• 873011-70-2 methyl 1-(4'-hydroxybiphenyl-4-yl)cyclopropane-carboxylate 
• 1423689-63-7 C₃₀H₂₇ClN₂O₅ 
• 1257213-60-7 1-(4'-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid 
• 1423689-66-0 C₃₀H₂₇ClN₂O₅ 
• 1265630-54-3 C₂₉H₂₅ClN₂O₅ 
• 1423700-73-5 methyl 1-[4-(4-bromophenyl)phenyl]cyclopropanecarboxylate 
• 1423700-75-7 1-[4'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid methyl ester 
• 1423689-69-3 C₃₀H₂₇ClN₂O₄S 
• 1423683-81-1 C₂₉H₂₅ClN₂O₄S 
• 1423689-93-3 C₄₀H₄₃ClN₂O₅Si 
• 1423689-96-6 C₃₅H₃₁ClN₂O₅ 
• 1423701-52-3 C₃₄H₂₉ClN₂O₄ 
• 1423684-54-1 C₃₃H₂₇ClN₂O₄ 
• 1423689-99-9 C₂₈H₂₅ClN₄O₄ 

Relevant articles and documents

Lysophosphatidic acid receptor antagonists and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.